2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1347

Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis: Characteristics, Treatment and Outcome in 251 Cases from the Literature

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1835

Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1721

Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1782

Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1481

Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1524

Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1442

Suppression of Acute Arthritis By N-Methyl-3,4-Dichloropropionaniline (N-MeDCPA), a Reversible Orai Calcium Channel Inhibitor

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1460

Suppression of Cholesterol Levels and Impairment in Cholesterol Efflux By HDL in K/BxN Mice Is Associated with a Specific Cytokine/Chemokine Profile

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1166

Survey on the Understanding and Practice of T2T for Nurses Engaged in Medical Treatment of Rheumatoid Arthritis

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1641

Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1733

Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1416

Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1514

Symptoms of Depression and Anxiety Predict Worse Disease Activity and Functional Disability in a Cohort of Established Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1091

Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1099

Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis

Biology and Pathology of Bone and Joint - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].